MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option
MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering...
PR Newswire·4d ago
MetaVia Stock Slides After Pricing Public Offering
(RTTNews) - MetaVia Inc. (MTVA) shares traded at $3.4050, down 39.03% or $2.18 lower, after the company announced the pricing of an $8.1 million underwritten public offering...
Nasdaq News: Markets·5d ago
MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering
MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering PR Newswire CAMBRIDGE, Mass., Jan. 15, 2026...
PR Newswire·5d ago
MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile
MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic...
PR Newswire·15d ago
MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference
MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference PR Newswire CAMBRIDGE, Mass., Dec. 29...
PR Newswire·22d ago
MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement
MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting 2025
MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting 2025 MetaVia Presents Positive New Phase 2a Data on Vanoglipel...